PAFAH2 and pulmonary arterial hypertension: In the future, we hope to develop a valuable therapeutic method using ω-3 epoxides for the purpose of suppressing pulmonary vascular remodeling in PAH patients with PAF-AH2 mutations who cannot be effectively treated with pulmonary artery dilators.